Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ardea Biosciences has announced positive preclinical data on the company's next generation non-nucleoside reverse transcriptase inhibitor family of compounds.
Subscribe to our email newsletter
The data showed that the compounds demonstrated potent activity against the human-immunodeficiency virus, including non-nucleoside reverse transcriptase inhibitor (NNRTI)- resistant strains, with the potential for improved performance over current NNRTIs.
The compounds in this NNRTI series are potent against both wild-type and the most common NNRTI-resistant viruses and are more active than efavirenz (Sustiva, BMS) and nevirapine (Viramune, Boehringer-Ingelheim) against a broad panel of NNRTI-resistant clinical isolates.
Barry Quart, president and CEO of Ardea, said: “Our lead NNRTI, RDEA806, has shown the potential to match this profile and we are preparing to progress it into a Phase IIb trial later this quarter. An important part of our business strategy is to progress an additional next generation NNRTI into Phase I later this year.”